News Releases

CAMBRIDGE, Mass., Aug. 29, 2024 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical-stage immunology company advancing RNA therapeutics to conquer cancer, announced today its participation in the following investor conferences:

• 22^nd Annual Morgan Stanley Healthcare Conference, September 4-6, 2024, in New York, NY
• Wells Fargo Annual Healthcare Conference, September 4-6, 2024, in Boston, MA
• Chardan's 3^rd Annual SPICI Symposium, September 8-10, 2024, in San Diego, CA
• 4^th Annual Needham Private Biotech Company Virtual 1x1 Forum, October 8-9, 2024

During these events, Company management will participate in one-on-one meetings with investors.

About Myeloid Therapeutics

Myeloid Therapeutics is a clinical stage immunology company, engineering cutting-edge RNA technology to program immune cells to combat cancer and other deadly diseases. Myeloid is headquartered in Cambridge, MA.

For additional information, please visit, https://www.myeloidtx.com/ and follow us on LinkedIn and X/Twitter.  For collaborative interests, write to partnering@myeloidtx.com.

Investor Contact
Amy Conrad
Juniper Point
Amy@juniper-point.com

SOURCE Myeloid Therapeutics, Inc.